Injectable or oral: why most peptides are injected

Most therapeutic peptides are given by injection, and the reason is neither convenience nor tradition: the digestive tract destroys them. Their chemical properties make the stomach and intestinal enzymes hydrolyse them before they can reach the bloodstream. Getting one to work as a pill required inventing something to get around that obstacle, and it has been done.

Why the digestive tract is a problem

A peptide is a chain of amino acids joined by amide bonds. That same bond is what food proteins use, and the digestive system exists precisely to break it.

The intrinsic properties of peptides do the rest: they lack the secondary and tertiary structure that protects the chain in a protein, so they remain exposed to hydrolysis. The result is that most therapeutic peptides do not survive the digestive journey. That is why these treatments are always considered under prescription; the peptide therapy protocol explains how that follow-up is structured.

What had to be invented to get a pill

The solution was not to shield the peptide inside a capsule, but to pair it with another molecule that opens the way.

These are called permeation enhancers, and they work through two mechanisms at once. First, they reduce the efficacy of digestive enzymes, so less of the peptide is destroyed. Second, and this is the interesting part, they increase its lipophilicity, meaning its affinity for fats, which improves absorption through the gastric membrane into the general circulation.

With one such enhancer, the first oral formulation of a GLP-1 analogue was approved for treating type 2 diabetes. Co-formulation has also been used with other peptides, such as octreotide and insulin, which are in clinical trials by this route.

The other route: making the injection less frequent

For peptides that cannot be taken orally, the strategy has been the opposite: rather than avoiding the injection, reduce how often it is needed.

That is where chemical modification comes in. One concrete case shows it clearly. Semaglutide conjugated with a long-chain fatty acid, the 18-carbon palmitic acid, was approved for once-weekly subcutaneous administration, and shows greater plasma stability than other GLP-1 analogues.

The fatty acid chain is not decoration: it is what keeps the molecule circulating longer before elimination. It is the same logic discussed when looking at peptide half-life.

What is still under study

Research continues along several lines at once. Beyond permeation enhancers, enzyme inhibitors and hydrogels are being studied to enable oral delivery. There is also work on pulmonary administration, transdermal delivery, and implantable pumps, including inhalable insulins and micro-implantable pumps for insulin delivery. These routes are not yet settled for general use.

What this means for someone receiving treatment

For a patient, the difference between a pill and a weekly injection is rarely neutral. It affects routine, fear of needles, and consistency. The literature notes that longer-acting analogues achieve better adherence, along with lower administration frequency and fewer adverse effects.

Two things that are often mixed together should be kept apart. A peptide being available orally does not make it over-the-counter: these are prescription medicines. And a formulation being compounded does not mean it is approved as a finished product.

On that last point: the base active ingredient holds FDA approval in its brand-name reference medicines. Personalised compounded formulations are prepared and dispensed by state-licensed 503A pharmacies under strict individualised medical prescription following a clinical consultation. A compounded medicine is not an FDA-approved equivalent of a brand-name product.

Frequently asked questions

Why is insulin injected rather than taken?

Because the digestive tract degrades it before it reaches the bloodstream. It is the same obstacle affecting other peptides, and it explains why specific permeation enhancers were needed in each case.

So do oral peptides already exist?

At least one oral formulation has been approved, achieved through co-formulation with a permeation enhancer. It is not a route available for every peptide: it depends on the specific molecule.

Is a weekly injection worse than a daily pill?

It depends on the person, and the prescribing professional weighs it. Adherence is a real clinical factor, and for some people a single weekly administration is more sustainable than a daily routine.

Are inhaled or transdermal peptides already in use?

There are active research lines, including inhalable insulins and implantable pumps. They are not yet a mainstream route.

Can I choose my route of administration?

No. The route is part of the prescription and depends on each patient's profile. Individual results vary according to each person's biological response.

If you want to know which option fits your case

A licensed professional reviews your history, your medication, and your background before any treatment is considered, and follow-up continues after the initial consultation.

Start your clinical evaluation →

Sources

1. Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C. Therapeutic peptides: current applications and future directions. *Signal Transduction and Targeted Therapy.* 2022;7(1):48. doi:10.1038/s41392-022-00904-4. Licence CC BY 4.0.
2. FDA. Compounding Laws and Policies. `https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies`

Medical Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Always consult your physician before making any changes to your medication or lifestyle regimen.